AustralieFrV1, PascalFrancis, Corpus, bibRecord, 001723

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

Identifieur interne : 001723 ( PascalFrancis/Corpus ); précédent : 001722; suivant : 001724

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

Auteurs : MICHELLE HONG ; Anne-Laure Puaux ; Caleb Huang ; Laure Loumagne ; Charlene Tow ; Charles Mackay ; Masashi Kato ; Armelle Prevost-Blondel ; Marie-Françoise Avril ; Alessandra Nardin ; Jean-Pierre Abastado

Source :

Cancer research : (Baltimore) [ 0008-5472 ] ; 2011.

RBID : Pascal:12-0020313

Descripteurs français

Pascal (Inist)
- Chimiothérapie, Voie intratumorale, Expression génique, Chimiokine, Cancer de la peau, Lymphocyte T, Médicament, Tumeur maligne, Dacarbazine, Témozolomide, Cisplatine, In vitro, Mécanisme action, Anticancéreux.

English descriptors

KwdEn :
- Antineoplastic agent, Chemokine, Chemotherapy, Cisplatin, Dacarbazine, Drug, Gene expression, In vitro, Intratumoral administration, Malignant tumor, Mechanism of action, Skin cancer, T-Lymphocyte, Temozolomide.

Abstract

T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy.

Notice en format standard (ISO 2709)

Pour connaître la documentation sur le format Inist Standard.

A01	`01`	`1`		`@0 0008-5472`
A02	`01`			`@0 CNREA8`
A03		`1`		`@0 Cancer res. : (Baltimore)`
A05				`@2 71`
A06				`@2 22`
A08	`01`	`1`	`ENG`	`@1 Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control`
A11	`01`	`1`		`@1 MICHELLE HONG`
A11	`02`	`1`		`@1 PUAUX (Anne-Laure)`
A11	`03`	`1`		`@1 HUANG (Caleb)`
A11	`04`	`1`		`@1 LOUMAGNE (Laure)`
A11	`05`	`1`		`@1 TOW (Charlene)`
A11	`06`	`1`		`@1 MACKAY (Charles)`
A11	`07`	`1`		`@1 KATO (Masashi)`
A11	`08`	`1`		`@1 PREVOST-BLONDEL (Armelle)`
A11	`09`	`1`		`@1 AVRIL (Marie-Françoise)`
A11	`10`	`1`		`@1 NARDIN (Alessandra)`
A11	`11`	`1`		`@1 ABASTADO (Jean-Pierre)`
A14	`01`			`@1 Singapore Immunology Network, BMSI, A-STAR @2 Singapore @3 SGP @Z 1 aut. @Z 2 aut. @Z 3 aut. @Z 4 aut. @Z 5 aut. @Z 10 aut. @Z 11 aut.`
A14	`02`			`@1 Faculty of Medicine, Monash University, Clayton @2 Victoria @3 AUS @Z 6 aut.`
A14	`03`			`@1 College of Life and Health Sciences, Chubu University @2 Aichi @3 JPN @Z 7 aut.`
A14	`04`			`@1 Institut Cochin, Universite Paris Descartes, CNRS UMR 8104 @3 FRA @Z 8 aut. @Z 9 aut.`
A14	`05`			`@1 Dermatology Department, Cochin Hospital, AP-HP, University Paris Descartes @3 FRA @Z 9 aut.`
A14	`06`			`@1 INSERM @2 U567, Paris @3 FRA @Z 8 aut. @Z 9 aut.`
A20				`@1 6997-7009`
A21				`@1 2011`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5088 @5 354000507350680100`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 37 ref.`
A47	`01`	`1`		`@0 12-0020313`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Cancer research : (Baltimore)`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy.
C02	`01`	`X`		`@0 002B02R`
C02	`02`	`X`		`@0 002B04`
C02	`03`	`X`		`@0 002B08A`
C03	`01`	`X`	`FRE`	`@0 Chimiothérapie @5 01`
C03	`01`	`X`	`ENG`	`@0 Chemotherapy @5 01`
C03	`01`	`X`	`SPA`	`@0 Quimioterapia @5 01`
C03	`02`	`X`	`FRE`	`@0 Voie intratumorale @5 03`
C03	`02`	`X`	`ENG`	`@0 Intratumoral administration @5 03`
C03	`02`	`X`	`SPA`	`@0 Vía intratumoral @5 03`
C03	`03`	`X`	`FRE`	`@0 Expression génique @5 04`
C03	`03`	`X`	`ENG`	`@0 Gene expression @5 04`
C03	`03`	`X`	`SPA`	`@0 Expresión genética @5 04`
C03	`04`	`X`	`FRE`	`@0 Chimiokine @5 05`
C03	`04`	`X`	`ENG`	`@0 Chemokine @5 05`
C03	`04`	`X`	`SPA`	`@0 Quimioquina @5 05`
C03	`05`	`X`	`FRE`	`@0 Cancer de la peau @2 NM @5 06`
C03	`05`	`X`	`ENG`	`@0 Skin cancer @2 NM @5 06`
C03	`05`	`X`	`SPA`	`@0 Cáncer de piel @2 NM @5 06`
C03	`06`	`X`	`FRE`	`@0 Lymphocyte T @5 07`
C03	`06`	`X`	`ENG`	`@0 T-Lymphocyte @5 07`
C03	`06`	`X`	`SPA`	`@0 Linfocito T @5 07`
C03	`07`	`X`	`FRE`	`@0 Médicament @5 08`
C03	`07`	`X`	`ENG`	`@0 Drug @5 08`
C03	`07`	`X`	`SPA`	`@0 Medicamento @5 08`
C03	`08`	`X`	`FRE`	`@0 Tumeur maligne @2 NM @5 09`
C03	`08`	`X`	`ENG`	`@0 Malignant tumor @2 NM @5 09`
C03	`08`	`X`	`SPA`	`@0 Tumor maligno @2 NM @5 09`
C03	`09`	`X`	`FRE`	`@0 Dacarbazine @2 NK @2 FR @5 10`
C03	`09`	`X`	`ENG`	`@0 Dacarbazine @2 NK @2 FR @5 10`
C03	`09`	`X`	`SPA`	`@0 Dacarbazina @2 NK @2 FR @5 10`
C03	`10`	`X`	`FRE`	`@0 Témozolomide @2 NK @2 FR @5 11`
C03	`10`	`X`	`ENG`	`@0 Temozolomide @2 NK @2 FR @5 11`
C03	`10`	`X`	`SPA`	`@0 Temozolomida @2 NK @2 FR @5 11`
C03	`11`	`X`	`FRE`	`@0 Cisplatine @2 NK @2 FR @5 12`
C03	`11`	`X`	`ENG`	`@0 Cisplatin @2 NK @2 FR @5 12`
C03	`11`	`X`	`SPA`	`@0 Cisplatino @2 NK @2 FR @5 12`
C03	`12`	`X`	`FRE`	`@0 In vitro @5 13`
C03	`12`	`X`	`ENG`	`@0 In vitro @5 13`
C03	`12`	`X`	`SPA`	`@0 In vitro @5 13`
C03	`13`	`X`	`FRE`	`@0 Mécanisme action @5 14`
C03	`13`	`X`	`ENG`	`@0 Mechanism of action @5 14`
C03	`13`	`X`	`SPA`	`@0 Mecanismo acción @5 14`
C03	`14`	`X`	`FRE`	`@0 Anticancéreux @5 23`
C03	`14`	`X`	`ENG`	`@0 Antineoplastic agent @5 23`
C03	`14`	`X`	`SPA`	`@0 Anticanceroso @5 23`
C07	`01`	`X`	`FRE`	`@0 Traitement`
C07	`01`	`X`	`ENG`	`@0 Treatment`
C07	`01`	`X`	`SPA`	`@0 Tratamiento`
C07	`02`	`X`	`FRE`	`@0 Cancer @2 NM`
C07	`02`	`X`	`ENG`	`@0 Cancer @2 NM`
C07	`02`	`X`	`SPA`	`@0 Cáncer @2 NM`
C07	`03`	`X`	`FRE`	`@0 Pathologie de la peau @5 37`
C07	`03`	`X`	`ENG`	`@0 Skin disease @5 37`
C07	`03`	`X`	`SPA`	`@0 Piel patología @5 37`
C07	`04`	`X`	`FRE`	`@0 Agent alkylant @5 38`
C07	`04`	`X`	`ENG`	`@0 Alkylating agent @5 38`
C07	`04`	`X`	`SPA`	`@0 Agente alquilante @5 38`
C07	`05`	`X`	`FRE`	`@0 Platine II Complexe @2 NC @2 NA @5 39`
C07	`05`	`X`	`ENG`	`@0 Platinum II Complexes @2 NC @2 NA @5 39`
C07	`05`	`X`	`SPA`	`@0 Platino II Complejo @2 NC @2 NA @5 39`
N21				`@1 009`

Format Inist (serveur)

NO :	PASCAL 12-0020313 INIST
ET :	Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
AU :	MICHELLE HONG; PUAUX (Anne-Laure); HUANG (Caleb); LOUMAGNE (Laure); TOW (Charlene); MACKAY (Charles); KATO (Masashi); PREVOST-BLONDEL (Armelle); AVRIL (Marie-Françoise); NARDIN (Alessandra); ABASTADO (Jean-Pierre)
AF :	Singapore Immunology Network, BMSI, A-STAR/Singapore/Singapour (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 10 aut., 11 aut.); Faculty of Medicine, Monash University, Clayton/Victoria/Australie (6 aut.); College of Life and Health Sciences, Chubu University/Aichi/Japon (7 aut.); Institut Cochin, Universite Paris Descartes, CNRS UMR 8104/France (8 aut., 9 aut.); Dermatology Department, Cochin Hospital, AP-HP, University Paris Descartes/France (9 aut.); INSERM/U567, Paris/France (8 aut., 9 aut.)
DT :	Publication en série; Niveau analytique
SO :	Cancer research : (Baltimore); ISSN 0008-5472; Coden CNREA8; Etats-Unis; Da. 2011; Vol. 71; No. 22; Pp. 6997-7009; Bibl. 37 ref.
LA :	Anglais
EA :	T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy.
CC :	002B02R; 002B04; 002B08A
FD :	Chimiothérapie; Voie intratumorale; Expression génique; Chimiokine; Cancer de la peau; Lymphocyte T; Médicament; Tumeur maligne; Dacarbazine; Témozolomide; Cisplatine; In vitro; Mécanisme action; Anticancéreux
FG :	Traitement; Cancer; Pathologie de la peau; Agent alkylant; Platine II Complexe
ED :	Chemotherapy; Intratumoral administration; Gene expression; Chemokine; Skin cancer; T-Lymphocyte; Drug; Malignant tumor; Dacarbazine; Temozolomide; Cisplatin; In vitro; Mechanism of action; Antineoplastic agent
EG :	Treatment; Cancer; Skin disease; Alkylating agent; Platinum II Complexes
SD :	Quimioterapia; Vía intratumoral; Expresión genética; Quimioquina; Cáncer de piel; Linfocito T; Medicamento; Tumor maligno; Dacarbazina; Temozolomida; Cisplatino; In vitro; Mecanismo acción; Anticanceroso
LO :	INIST-5088.354000507350680100
ID :	12-0020313

Links to Exploration step

Pascal:12-0020313

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control</title>
<author><name sortKey="Michelle Hong" sort="Michelle Hong" uniqKey="Michelle Hong" last="Michelle Hong">MICHELLE HONG</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Puaux, Anne Laure" sort="Puaux, Anne Laure" uniqKey="Puaux A" first="Anne-Laure" last="Puaux">Anne-Laure Puaux</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huang, Caleb" sort="Huang, Caleb" uniqKey="Huang C" first="Caleb" last="Huang">Caleb Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Loumagne, Laure" sort="Loumagne, Laure" uniqKey="Loumagne L" first="Laure" last="Loumagne">Laure Loumagne</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tow, Charlene" sort="Tow, Charlene" uniqKey="Tow C" first="Charlene" last="Tow">Charlene Tow</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mackay, Charles" sort="Mackay, Charles" uniqKey="Mackay C" first="Charles" last="Mackay">Charles Mackay</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Medicine, Monash University, Clayton</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kato, Masashi" sort="Kato, Masashi" uniqKey="Kato M" first="Masashi" last="Kato">Masashi Kato</name>
<affiliation><inist:fA14 i1="03"><s1>College of Life and Health Sciences, Chubu University</s1>
<s2>Aichi</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Prevost Blondel, Armelle" sort="Prevost Blondel, Armelle" uniqKey="Prevost Blondel A" first="Armelle" last="Prevost-Blondel">Armelle Prevost-Blondel</name>
<affiliation><inist:fA14 i1="04"><s1>Institut Cochin, Universite Paris Descartes, CNRS UMR 8104</s1>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>INSERM</s1>
<s2>U567, Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Avril, Marie Francoise" sort="Avril, Marie Francoise" uniqKey="Avril M" first="Marie-Françoise" last="Avril">Marie-Françoise Avril</name>
<affiliation><inist:fA14 i1="04"><s1>Institut Cochin, Universite Paris Descartes, CNRS UMR 8104</s1>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Dermatology Department, Cochin Hospital, AP-HP, University Paris Descartes</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>INSERM</s1>
<s2>U567, Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nardin, Alessandra" sort="Nardin, Alessandra" uniqKey="Nardin A" first="Alessandra" last="Nardin">Alessandra Nardin</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Abastado, Jean Pierre" sort="Abastado, Jean Pierre" uniqKey="Abastado J" first="Jean-Pierre" last="Abastado">Jean-Pierre Abastado</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0020313</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 12-0020313 INIST</idno>
<idno type="RBID">Pascal:12-0020313</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001723</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control</title>
<author><name sortKey="Michelle Hong" sort="Michelle Hong" uniqKey="Michelle Hong" last="Michelle Hong">MICHELLE HONG</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Puaux, Anne Laure" sort="Puaux, Anne Laure" uniqKey="Puaux A" first="Anne-Laure" last="Puaux">Anne-Laure Puaux</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Huang, Caleb" sort="Huang, Caleb" uniqKey="Huang C" first="Caleb" last="Huang">Caleb Huang</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Loumagne, Laure" sort="Loumagne, Laure" uniqKey="Loumagne L" first="Laure" last="Loumagne">Laure Loumagne</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Tow, Charlene" sort="Tow, Charlene" uniqKey="Tow C" first="Charlene" last="Tow">Charlene Tow</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Mackay, Charles" sort="Mackay, Charles" uniqKey="Mackay C" first="Charles" last="Mackay">Charles Mackay</name>
<affiliation><inist:fA14 i1="02"><s1>Faculty of Medicine, Monash University, Clayton</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Kato, Masashi" sort="Kato, Masashi" uniqKey="Kato M" first="Masashi" last="Kato">Masashi Kato</name>
<affiliation><inist:fA14 i1="03"><s1>College of Life and Health Sciences, Chubu University</s1>
<s2>Aichi</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Prevost Blondel, Armelle" sort="Prevost Blondel, Armelle" uniqKey="Prevost Blondel A" first="Armelle" last="Prevost-Blondel">Armelle Prevost-Blondel</name>
<affiliation><inist:fA14 i1="04"><s1>Institut Cochin, Universite Paris Descartes, CNRS UMR 8104</s1>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>INSERM</s1>
<s2>U567, Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Avril, Marie Francoise" sort="Avril, Marie Francoise" uniqKey="Avril M" first="Marie-Françoise" last="Avril">Marie-Françoise Avril</name>
<affiliation><inist:fA14 i1="04"><s1>Institut Cochin, Universite Paris Descartes, CNRS UMR 8104</s1>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="05"><s1>Dermatology Department, Cochin Hospital, AP-HP, University Paris Descartes</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
<affiliation><inist:fA14 i1="06"><s1>INSERM</s1>
<s2>U567, Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Nardin, Alessandra" sort="Nardin, Alessandra" uniqKey="Nardin A" first="Alessandra" last="Nardin">Alessandra Nardin</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Abastado, Jean Pierre" sort="Abastado, Jean Pierre" uniqKey="Abastado J" first="Jean-Pierre" last="Abastado">Jean-Pierre Abastado</name>
<affiliation><inist:fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Cancer research : (Baltimore)</title>
<title level="j" type="abbreviated">Cancer res. : (Baltimore)</title>
<idno type="ISSN">0008-5472</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Cancer research : (Baltimore)</title>
<title level="j" type="abbreviated">Cancer res. : (Baltimore)</title>
<idno type="ISSN">0008-5472</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic agent</term>
<term>Chemokine</term>
<term>Chemotherapy</term>
<term>Cisplatin</term>
<term>Dacarbazine</term>
<term>Drug</term>
<term>Gene expression</term>
<term>In vitro</term>
<term>Intratumoral administration</term>
<term>Malignant tumor</term>
<term>Mechanism of action</term>
<term>Skin cancer</term>
<term>T-Lymphocyte</term>
<term>Temozolomide</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Chimiothérapie</term>
<term>Voie intratumorale</term>
<term>Expression génique</term>
<term>Chimiokine</term>
<term>Cancer de la peau</term>
<term>Lymphocyte T</term>
<term>Médicament</term>
<term>Tumeur maligne</term>
<term>Dacarbazine</term>
<term>Témozolomide</term>
<term>Cisplatine</term>
<term>In vitro</term>
<term>Mécanisme action</term>
<term>Anticancéreux</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0008-5472</s0>
</fA01>
<fA02 i1="01"><s0>CNREA8</s0>
</fA02>
<fA03 i2="1"><s0>Cancer res. : (Baltimore)</s0>
</fA03>
<fA05><s2>71</s2>
</fA05>
<fA06><s2>22</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MICHELLE HONG</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>PUAUX (Anne-Laure)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>HUANG (Caleb)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LOUMAGNE (Laure)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>TOW (Charlene)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MACKAY (Charles)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>KATO (Masashi)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>PREVOST-BLONDEL (Armelle)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>AVRIL (Marie-Françoise)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>NARDIN (Alessandra)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>ABASTADO (Jean-Pierre)</s1>
</fA11>
<fA14 i1="01"><s1>Singapore Immunology Network, BMSI, A-STAR</s1>
<s2>Singapore</s2>
<s3>SGP</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Faculty of Medicine, Monash University, Clayton</s1>
<s2>Victoria</s2>
<s3>AUS</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>College of Life and Health Sciences, Chubu University</s1>
<s2>Aichi</s2>
<s3>JPN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Institut Cochin, Universite Paris Descartes, CNRS UMR 8104</s1>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Dermatology Department, Cochin Hospital, AP-HP, University Paris Descartes</s1>
<s3>FRA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>INSERM</s1>
<s2>U567, Paris</s2>
<s3>FRA</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
</fA14>
<fA20><s1>6997-7009</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5088</s2>
<s5>354000507350680100</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>37 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0020313</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Cancer research : (Baltimore)</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02R</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="03" i2="X"><s0>002B08A</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Chimiothérapie</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Chemotherapy</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Quimioterapia</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Voie intratumorale</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Intratumoral administration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Vía intratumoral</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Expression génique</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Gene expression</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Expresión genética</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Chimiokine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Chemokine</s0>
<s5>05</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Quimioquina</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Cancer de la peau</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Skin cancer</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Cáncer de piel</s0>
<s2>NM</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Lymphocyte T</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>T-Lymphocyte</s0>
<s5>07</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Linfocito T</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Médicament</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Drug</s0>
<s5>08</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Medicamento</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Tumeur maligne</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Malignant tumor</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Tumor maligno</s0>
<s2>NM</s2>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Dacarbazine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dacarbazine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Dacarbazina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Témozolomide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Temozolomide</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Temozolomida</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Cisplatine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Cisplatin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Cisplatino</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>In vitro</s0>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Mécanisme action</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Mechanism of action</s0>
<s5>14</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Mecanismo acción</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>23</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Traitement</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Treatment</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Tratamiento</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cancer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Cáncer</s0>
<s2>NM</s2>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Pathologie de la peau</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Skin disease</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Piel patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Agent alkylant</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Alkylating agent</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Agente alquilante</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Platine II Complexe</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Platinum II Complexes</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Platino II Complejo</s0>
<s2>NC</s2>
<s2>NA</s2>
<s5>39</s5>
</fC07>
<fN21><s1>009</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 12-0020313 INIST</NO>
<ET>Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control</ET>
<AU>MICHELLE HONG; PUAUX (Anne-Laure); HUANG (Caleb); LOUMAGNE (Laure); TOW (Charlene); MACKAY (Charles); KATO (Masashi); PREVOST-BLONDEL (Armelle); AVRIL (Marie-Françoise); NARDIN (Alessandra); ABASTADO (Jean-Pierre)</AU>
<AF>Singapore Immunology Network, BMSI, A-STAR/Singapore/Singapour (1 aut., 2 aut., 3 aut., 4 aut., 5 aut., 10 aut., 11 aut.); Faculty of Medicine, Monash University, Clayton/Victoria/Australie (6 aut.); College of Life and Health Sciences, Chubu University/Aichi/Japon (7 aut.); Institut Cochin, Universite Paris Descartes, CNRS UMR 8104/France (8 aut., 9 aut.); Dermatology Department, Cochin Hospital, AP-HP, University Paris Descartes/France (9 aut.); INSERM/U567, Paris/France (8 aut., 9 aut.)</AF>
<DT>Publication en série; Niveau analytique</DT>
<SO>Cancer research : (Baltimore); ISSN 0008-5472; Coden CNREA8; Etats-Unis; Da. 2011; Vol. 71; No. 22; Pp. 6997-7009; Bibl. 37 ref.</SO>
<LA>Anglais</LA>
<EA>T-cell infiltration is known to impact tumor growth and is associated with cancer patient survival. However, the molecular cues that favor T-cell infiltration remain largely undefined. Here, using a genetically engineered mouse model of melanoma, we show that CXCR3 ligands and CCL5 synergize to attract effector T cells into cutaneous metastases, and their expression inhibits tumor growth. Treatment of tumor-bearing mice with chemotherapy induced intratumoral expression of these chemokines and favored T-cell infiltration into cutaneous tumors. In patients with melanoma, these chemokines were also upregulated in chemotherapy-sensitive lesions following chemotherapy, and correlated with T-cell infiltration, tumor control, and patient survival. We found that dacarbazine, temozolomide, and cisplatin induced expression of T-cell-attracting chemokines in several human melanoma cell lines in vitro. These data identify the induction of intratumoral expression of chemokines as a novel cell-extrinsic mechanism of action of chemotherapy that results in the recruitment of immune cells with antitumor activity. Therefore, identifying chemotherapeutic drugs able to induce the expression of T-cell-attracting chemokines in cancer cells may represent a novel strategy to improve the efficacy of cancer immunotherapy.</EA>
<CC>002B02R; 002B04; 002B08A</CC>
<FD>Chimiothérapie; Voie intratumorale; Expression génique; Chimiokine; Cancer de la peau; Lymphocyte T; Médicament; Tumeur maligne; Dacarbazine; Témozolomide; Cisplatine; In vitro; Mécanisme action; Anticancéreux</FD>
<FG>Traitement; Cancer; Pathologie de la peau; Agent alkylant; Platine II Complexe</FG>
<ED>Chemotherapy; Intratumoral administration; Gene expression; Chemokine; Skin cancer; T-Lymphocyte; Drug; Malignant tumor; Dacarbazine; Temozolomide; Cisplatin; In vitro; Mechanism of action; Antineoplastic agent</ED>
<EG>Treatment; Cancer; Skin disease; Alkylating agent; Platinum II Complexes</EG>
<SD>Quimioterapia; Vía intratumoral; Expresión genética; Quimioquina; Cáncer de piel; Linfocito T; Medicamento; Tumor maligno; Dacarbazina; Temozolomida; Cisplatino; In vitro; Mecanismo acción; Anticanceroso</SD>
<LO>INIST-5088.354000507350680100</LO>
<ID>12-0020313</ID>
</server>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001723 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 001723 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Corpus
   |type=    RBID
   |clé=     Pascal:12-0020313
   |texte=   Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

Chemotherapy Induces Intratumoral Expression of Chemokines in Cutaneous Melanoma, Favoring T-cell Infiltration and Tumor Control

Source :

Descripteurs français

English descriptors

Abstract

Notice en format standard (ISO 2709)

Format Inist (serveur)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri